MA41462A - Méthode de traitement de maladies - Google Patents

Méthode de traitement de maladies

Info

Publication number
MA41462A
MA41462A MA041462A MA41462A MA41462A MA 41462 A MA41462 A MA 41462A MA 041462 A MA041462 A MA 041462A MA 41462 A MA41462 A MA 41462A MA 41462 A MA41462 A MA 41462A
Authority
MA
Morocco
Prior art keywords
diseases
treatment
Prior art date
Application number
MA041462A
Other languages
English (en)
Other versions
MA41462B1 (fr
Inventor
Roni Mamluk
Original Assignee
Chiasma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56552726&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA41462(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiasma Inc filed Critical Chiasma Inc
Publication of MA41462A publication Critical patent/MA41462A/fr
Publication of MA41462B1 publication Critical patent/MA41462B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
MA41462A 2015-02-03 2016-02-03 Traitement l' acromégalie avec de l' octréotide par voie orale MA41462B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562111369P 2015-02-03 2015-02-03
US201562136012P 2015-03-20 2015-03-20
PCT/US2016/016384 WO2016126830A1 (fr) 2015-02-03 2016-02-03 Méthode de traitement de maladies
EP16747195.2A EP3253401B1 (fr) 2015-02-03 2016-02-03 Traitement l' acromégalie avec de l' octréotide par voie orale

Publications (2)

Publication Number Publication Date
MA41462A true MA41462A (fr) 2021-05-12
MA41462B1 MA41462B1 (fr) 2025-04-30

Family

ID=56552726

Family Applications (1)

Application Number Title Priority Date Filing Date
MA41462A MA41462B1 (fr) 2015-02-03 2016-02-03 Traitement l' acromégalie avec de l' octréotide par voie orale

Country Status (20)

Country Link
US (9) US10238709B2 (fr)
EP (2) EP4527456A3 (fr)
AU (3) AU2016215350B2 (fr)
CA (1) CA2975599A1 (fr)
DK (1) DK3253401T3 (fr)
ES (1) ES3029566T3 (fr)
FI (1) FI3253401T3 (fr)
HR (1) HRP20250645T1 (fr)
HU (1) HUE071943T2 (fr)
IL (2) IL253706A0 (fr)
LT (1) LT3253401T (fr)
MA (1) MA41462B1 (fr)
MD (1) MD3253401T2 (fr)
PL (1) PL3253401T3 (fr)
PT (1) PT3253401T (fr)
RS (1) RS66942B1 (fr)
SI (1) SI3253401T1 (fr)
SM (1) SMT202500243T1 (fr)
WO (1) WO2016126830A1 (fr)
ZA (3) ZA201705877B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ591810A (en) 2008-09-17 2012-12-21 Chiasma Inc Pharmaceutical compositions and related methods of delivery the composition comprises a medium chain fatty acid
HK1245115A1 (zh) * 2014-12-10 2018-08-24 Amryt Endo, Inc. 口腔奥曲肽与其他治疗剂联合应用
PL3253401T3 (pl) * 2015-02-03 2025-08-04 Amryt Endo, Inc. Leczenie akromegalii oktreotydem doustnym
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods
US20220202911A1 (en) * 2020-12-28 2022-06-30 Amryt Endo, Inc. Oral octreotide therapy in combination with digoxin or lisinopril
US20240307504A1 (en) * 2021-01-21 2024-09-19 Nbo Pharma Llc Intranasal formulations and delivery of somatostatin mimetics and uses thereof
IL305437A (en) * 2021-02-24 2023-10-01 Nbo Pharma Llc Medical methods and combinations for the treatment of unexplained intracranial hypertension and cluster headaches
WO2022251212A2 (fr) * 2021-05-25 2022-12-01 Crinetics Pharmaceuticals, Inc. Utilisations d'un modulateur de somatostatine pour le traitement d'une maladie

Family Cites Families (194)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4411890A (en) 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
SE376722B (fr) 1971-03-30 1975-06-09 S E Friberg
BE795516A (fr) 1972-02-17 1973-08-16 Ciba Geigy Preparations de peptides huileuses et injectables et procede pour leur preparation
US4489097A (en) 1976-07-28 1984-12-18 The Procter & Gamble Company Intravenous solutions with antimicrobial agent
JPS53107408A (en) 1977-02-28 1978-09-19 Yamanouchi Pharmaceut Co Ltd Micellar preparation for rectal infusion
GB2051574B (en) 1979-05-10 1984-01-18 Kyoto Pharma Ind Adjuvant for promoting absorption of pharmacologically active substances through the rectum
US4544500A (en) 1982-04-14 1985-10-01 Scripps Clinic And Research Foundation Synthetic foot and mouth disease antigen
US4589881A (en) 1982-08-04 1986-05-20 La Jolla Cancer Research Foundation Polypeptide
US4508828A (en) 1983-03-21 1985-04-02 Immuno Nuclear Corporation Bioassay of parathyroid hormone
US4572915A (en) 1984-05-01 1986-02-25 Bioglan Laboratories Clear micellized solutions of fat soluble essential nutrients
US4985404A (en) 1984-10-04 1991-01-15 Monsanto Company Prolonged release of biologically active polypeptides
US4650665A (en) 1985-02-08 1987-03-17 Ethicon, Inc. Controlled release of pharmacologically active agents from an absorbable biologically compatible putty-like composition
US4650787A (en) * 1985-04-25 1987-03-17 Schally Andrew Victor Biologically active octapeptides
US4732971A (en) 1985-06-03 1988-03-22 Eli Lilly And Company Synthetic vaccines for foot and mouth disease
HU198626B (en) 1986-05-27 1989-11-28 Sandoz Ag Process for producing pharmaceutical compositions comprising somatostatin analogues as active ingredient
DE3709861A1 (de) 1987-03-25 1988-10-06 Henkel Kgaa Emulgierende suppositoriengrundmassen und daraus hergestellte zaepfchen
US4839344A (en) 1987-06-12 1989-06-13 Eastman Kodak Company Polypeptide compounds having growth hormone releasing activity
DE3738236A1 (de) 1987-11-11 1989-05-24 Euro Celtique Sa Beisskapsel
FR2627696B1 (fr) 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
NZ228285A (en) 1988-03-11 1991-08-27 Teikoku Seiyaku Kk Pharmaceutical composition comprising a polypeptide and adapted for intravaginal administration
GB8822857D0 (en) 1988-09-29 1988-11-02 Patralan Ltd Pharmaceutical formulations
ZA898331B (en) 1988-11-22 1990-07-25 Hoffmann La Roche Pharmaceutical compositions
NZ233403A (en) 1989-04-28 1992-09-25 Mcneil Ppc Inc Simulated capsule-like medicament
ES2062543T3 (es) 1989-08-17 1994-12-16 Cortecs Ltd Formulaciones farmaceuticas.
US5665384A (en) 1990-04-06 1997-09-09 Rhone-Poulenc Rorer S.A. Oily capsules of ketoprofen
GB9013448D0 (en) 1990-06-15 1990-08-08 Sandoz Ltd Pharmaceutical resorption-improved somatostatin compositions,their preparation and use
SE9003100D0 (sv) 1990-09-28 1990-09-28 Kabivitrum Ab Lipid formulation system
IT1243435B (it) 1990-10-05 1994-06-10 Altergon Sa Composizioni farmaceutiche per uso topico comprendenti acido ialuronico sale sodico e sostanze disinfettanti
US5254331A (en) 1991-09-12 1993-10-19 Chanel, Inc. Skin cream composition
AU664719B2 (en) 1991-11-08 1995-11-30 Green Cross Corporation, The Pharmaceutical preparation containing prostaglandin compound for rectal or vaginal administration
US5206219A (en) 1991-11-25 1993-04-27 Applied Analytical Industries, Inc. Oral compositions of proteinaceous medicaments
US5478577A (en) 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5246716A (en) 1992-01-10 1993-09-21 W. Neudorff Gmbh Kg Fatty acid-based antifungal composition having residual activity
DE4203170A1 (de) 1992-02-05 1993-08-12 Basf Ag Verfahren zur herstellung von e-oximethern von phenylglyoxylsaeureestern
GB9203769D0 (en) 1992-02-21 1992-04-08 Sandoz Ltd Improvements in or relating to organic compounds
IL103224A (en) 1992-09-18 1998-08-16 Teva Pharma Stabilized pharmaceutical compositions containing derivatives of vitamins d2 and d3
US5288492A (en) 1992-11-13 1994-02-22 Morris Michael A Decongestant composition containing aloe vera
DK17093D0 (da) 1993-02-15 1993-02-15 Lyfjathroun H F Farmaceutisk praeparat til topisk administrering af antigener og/eller vacciner til pattedyr via slimhinder
IT1263840B (it) 1993-03-30 1996-09-04 Giuseppe Furiosi Formulazioni orali di ubidecarenone in forma di capsule
US5318781A (en) 1993-04-06 1994-06-07 Hoffmann-La Roche Inc. Absorption enhancement of antibiotics
SE9302135D0 (sv) 1993-06-18 1993-06-18 Kabi Pharmacia Ab New pharmaceutical composition
TW402506B (en) 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
US5506203C1 (en) 1993-06-24 2001-02-06 Astra Ab Systemic administration of a therapeutic preparation
US5462726A (en) 1993-12-17 1995-10-31 Bristol-Myers Squibb Company Method of inhibiting side effects of solvents containing ricinoleic acid or castor oil or derivatives thereof employing a thromboxane A2 receptor antagonist and pharmaceutical compositions containing such solvents
GB9405304D0 (en) 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US5561115A (en) 1994-08-10 1996-10-01 Bayer Corporation Low temperature albumin fractionation using sodium caprylate as a partitioning agent
GB9417524D0 (en) 1994-08-31 1994-10-19 Cortecs Ltd Pharmaceutical compositions
WO1996020001A1 (fr) 1994-12-28 1996-07-04 Teikoku Hormone Mfg. Co., Ltd. Preparation traversant la muqueuse
US5708017A (en) 1995-04-04 1998-01-13 Merck & Co., Inc. Stable, ready-to-use pharmaceutical paste composition containing proton pump inhibitors
US5827534A (en) 1995-05-24 1998-10-27 University Of Maryland At Baltimore Oral dosage composition comprising zonnula occludens toxin and a therapeutic agent for intestinal delivery
US6696413B2 (en) 1995-06-16 2004-02-24 Hexal Ag Pharmaceutical preparation with cyclosporin A
GB9516268D0 (en) 1995-08-08 1995-10-11 Danbiosyst Uk Compositiion for enhanced uptake of polar drugs from the colon
US5686488A (en) 1995-08-25 1997-11-11 Alcon Laboratories, Inc. Polyethoxylated castor oil products as anti-inflammatory agents
EP0760237A1 (fr) 1995-08-30 1997-03-05 Cipla Limited Microémulsions huile-dans-l'eau
US5665711A (en) 1995-12-12 1997-09-09 Yoshitomi Pharmaceutical Industries, Ltd. Antitumor composition for oral administration
US5858401A (en) 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
US6280745B1 (en) 1997-12-23 2001-08-28 Alliance Pharmaceutical Corp. Methods and compositions for the delivery of pharmaceutical agents and/or the prevention of adhesions
DK0889722T3 (da) 1996-03-28 2003-02-10 Takeda Chemical Industries Ltd Præparat med forsinket frigivelse og fremstilling deraf
US6214792B1 (en) 1996-04-12 2001-04-10 David Lew Simon Method for treating acute and severe diarrhea
US5726154A (en) 1996-06-28 1998-03-10 University Of Utah Research Foundation Stabilization and oral delivery of calcitonin
IL127956A0 (en) 1996-07-11 1999-11-30 Farmarc Nederland Bv Inclusion complex containing indole selective serotonin agonist
US6512010B1 (en) 1996-07-15 2003-01-28 Alza Corporation Formulations for the administration of fluoxetine
US5760096A (en) 1996-10-18 1998-06-02 Thornfeldt; Carl R. Potent penetration enhancers
US7091183B1 (en) 1996-12-03 2006-08-15 Boston Medical Center Corporation Specific antagonists for glucose-dependent insulinotropic polypeptide (GIP)
US6193986B1 (en) 1997-02-25 2001-02-27 The Nisshin Oil Mills, Ltd. Oily composition with increased stability and process for producing the same
JPH10265380A (ja) 1997-03-17 1998-10-06 Bristol Myers Squibb Co 抗ガン剤
ATE286715T1 (de) 1997-03-25 2005-01-15 Takeda Chemical Industries Ltd Gastrointestinale an der mucosa haftende pharmazeutische zusammensetzung
DE69807281T2 (de) 1997-05-14 2003-04-17 Mitsubishi Chemical Corp., Tokio/Tokyo Difluprednat enthaltende Zusammensetzungen
IT1296914B1 (it) 1997-12-01 1999-08-03 Maria Rosa Gasco Composizione farmaceutica comprendente microparticelle atte al passaggio transmucosale ed al superamento della barriera
IL123143A (en) 1998-02-02 2001-08-26 Agis Ind 1983 Ltd Pharmaceutical compositions containing mupirocin
JPH11246439A (ja) 1998-03-02 1999-09-14 Hisamitsu Pharmaceut Co Inc 経粘膜用吸収促進剤
DK1062952T3 (da) 1998-03-11 2003-11-24 Grelan Pharmaceutical Co Brusende enteropræparater
EP0950407B1 (fr) 1998-04-14 2002-09-04 Hisamitsu Pharmaceutical Co., Inc. Utilisation de l'antagoniste de GP IIb/IIIa pour l'obtention d'un médicament utilisable pour l'application transdermique par iontophorèse
EP1087989A1 (fr) 1998-06-26 2001-04-04 Pfizer Products Inc. Procede ameliore pour preparer des bases de schiff produits d'addition d'amines avec des aldehyde o-hydroxy et compositions de substances a base de ces produits
US6150333A (en) 1998-07-30 2000-11-21 Biomeasure, Inc. Methods of using a somatostatin analogue
US6284223B1 (en) 1998-10-15 2001-09-04 Fluoroprobe, Inc. Method for viewing tumor tissue located within a body cavity
IT1302682B1 (it) 1998-10-16 2000-09-29 Formenti Farmaceutici Spa Composizioni farmaceutiche orali contenenti buprenorfina
GB9823246D0 (en) 1998-10-24 1998-12-16 Danbiosyst Uk A nasal drug delivery composition
US6838091B2 (en) 1998-12-18 2005-01-04 Abbott Laboratories Formulations comprising lipid-regulating agents
US6368622B2 (en) 1999-01-29 2002-04-09 Abbott Laboratories Process for preparing solid formulations of lipid regulating agents with enhanced dissolution and absorption
WO2000047203A1 (fr) 1999-02-12 2000-08-17 Mqs, Inc. Formulation et systeme pour administration intra-orale de principes actifs
WO2000050012A1 (fr) 1999-02-22 2000-08-31 Elan Corporation, Plc Dose orale solide contenant un agent de potentialisation
US8119159B2 (en) 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US20070148228A1 (en) 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6383527B1 (en) 1999-03-04 2002-05-07 Nps Pharmaceuticals, Inc. Compositions comprising valerian extracts, isovaleric acid or derivatives thereof with a NSAID
US6632443B2 (en) 2000-02-23 2003-10-14 National Research Council Of Canada Water-soluble compositions of bioactive lipophilic compounds
JP2003501404A (ja) 1999-06-04 2003-01-14 デルルックス ファーマシューティカル コーポレイション 薬剤の脱水粒子からなる製剤およびこれの調製方法
US20030235595A1 (en) 1999-06-30 2003-12-25 Feng-Jing Chen Oil-containing, orally administrable pharmaceutical composition for improved delivery of a therapeutic agent
US6159935A (en) 1999-11-29 2000-12-12 Pharmacia & Upjohn Co. Method for preventing diarrhea
FR2803202B1 (fr) 2000-01-03 2004-04-16 Capsulis Compositions pharmaceutiques destinees a une adminstration par voie orale
GB0018891D0 (en) 2000-08-01 2000-09-20 Novartis Ag Organic compounds
CN1141974C (zh) 2000-06-07 2004-03-17 张昊 结肠定位释放的口服生物制剂
US6664234B1 (en) 2000-06-30 2003-12-16 Monsanto Technology Llc Non-aqueous injectable formulation preparation with pH adjusted for extended release of somatotropin
FR2811571B1 (fr) 2000-07-11 2002-10-11 Flamel Tech Sa Composition pharmaceutique orale, permettant la liberation controlee et l'absorption prolongee d'un principe actif
US20020091623A1 (en) 2000-12-04 2002-07-11 Daniels Alan F. System and methods for an electronic real estate trading environment
BR0208984A (pt) 2001-04-18 2004-06-29 Prometic Biosciences Inc ácidos graxos, glicerìdeos e análogos de comprimento de cadeia médio como fatores de sobrevivência e ativação de neutrófilos
WO2002092616A1 (fr) 2001-05-11 2002-11-21 Orasense, Ltd. Renforçateurs de permeation antisens
US6528667B2 (en) 2001-05-14 2003-03-04 Phoenix Research Corporation Phosphated castor oil and derivatives
US20030070584A1 (en) 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
BR0210867A (pt) 2001-07-06 2004-06-29 Lifecycle Pharma As Processo para a preparação de um material particulado, métodos para aglomeração controlada de um material sólido finamente disperso, para melhorar a biodisponibilidade de uma substância terapêutica e/ou profilaticamente ativa, e para melhorar a vida em prateleira de uma composição farmacêutica, material articulado, composição farmacêutica, uso de um veìculo, material particulado farmacêutico, e, uso de aluminossilicato de magnésio e/ou de aluminometassilicato de magnésio
US6720002B2 (en) 2001-07-20 2004-04-13 R.P. Scherer Technologies, Inc. Antihistamine formulations for soft capsule dosage forms
CN1335182A (zh) 2001-08-08 2002-02-13 华中科技大学 胰岛素口腔喷剂及其制备工艺
KR100425755B1 (ko) 2001-08-27 2004-04-03 주식회사 원진신약 이트라코나졸을 함유하는 조성물 및 그 제조방법
ES2280582T3 (es) 2001-09-19 2007-09-16 Elan Pharma International Limited Formulaciones de insulina en nanoparticulas.
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
CA2463067A1 (fr) 2001-10-26 2003-05-08 Sciclone Pharmaceuticals, Inc. Preparations pharmaceutiques comprenant des composes de xanthine substituee
AU2002351169B2 (en) 2001-11-26 2007-09-20 Intas Pharmaceuticals Limited Method for preparing and using polyoxyethylated castor oil in pharmaceutical compositions
US20060078618A1 (en) 2001-12-11 2006-04-13 Constantinides Panayiotis P Lipid particles and suspensions and uses thereof
TWI287986B (en) 2001-12-13 2007-10-11 Novartis Ag Use of Epothilones for the treatment of the carcinoid syndrome
ES2425738T3 (es) 2001-12-21 2013-10-17 Human Genome Sciences, Inc. Proteínas de fusión de la albúmina
US6890961B2 (en) 2002-02-01 2005-05-10 Micelle Products, Inc. Clear micellized formulations of β-carotene and method of treating leukoplakia
US20030162695A1 (en) 2002-02-27 2003-08-28 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
AU2003218306B2 (en) 2002-03-20 2006-09-14 Advanced Inhalation Research, Inc. Method for administration of growth hormone via pulmonary delivery
US20050287203A1 (en) 2002-05-08 2005-12-29 Nijs De H Formulation comprising testosteron undecanoate and castor oil
CZ294371B6 (cs) 2002-06-10 2004-12-15 Pliva - Lachema, A. S. Stabilizovaná farmaceutická kompozice na bázi polyoxyethylovaného ricinového oleje a způsob její přípravy
FR2842736B1 (fr) 2002-07-26 2005-07-22 Flamel Tech Sa Formulation pharmaceutique orale sous forme d'une pluralite de microcapsules permettant la liberation prolongee de principe(s) actif(s) peu soluble(s)
PT1542670E (pt) 2002-09-24 2013-07-11 Suntory Holdings Ltd Composição com efeitos na prevenção do declínio, melhoramento ou aumento de respostas normais de aptidões cognitivas de uma pessoa saudável
US7411039B2 (en) 2002-10-14 2008-08-12 Novo Nordisk A/S GLP-2 compounds, formulations, and uses thereof
US20040097419A1 (en) 2002-11-19 2004-05-20 Holger Petersen Organic compounds
LT1585548T (lt) 2002-12-09 2018-09-25 Abraxis Bioscience, Llc Farmakologinių agentų kompozicijos ir įvedimo būdai
US9682054B2 (en) 2003-02-07 2017-06-20 Prometic Pharma Smt Limited Medium-chain length fatty acids, glycerides and analogues as stimulators of erythropoiesis
US7803781B2 (en) 2003-02-28 2010-09-28 Isis Pharmaceuticals, Inc. Modulation of growth hormone receptor expression and insulin-like growth factor expression
US20040185170A1 (en) 2003-03-21 2004-09-23 Shubha Chungi Method for coating drug-containing particles and formulations and dosage units formed therefrom
GB0307082D0 (en) 2003-03-27 2003-04-30 Gyne Ideas Ltd Drug delivery device and method
DE10328905B4 (de) 2003-06-26 2015-07-09 Hochland Natec Gmbh Form- und Kühlvorrichtung
EP1648472A2 (fr) 2003-07-01 2006-04-26 Ranbaxy Laboratories, Ltd. Compositions orales stables de monohydrate d'azithromycine
WO2005021013A1 (fr) 2003-09-01 2005-03-10 Earthus, Inc. Polymere d'acides gras a chaine $g(b)-hydroxy courte a moyenne
JP2007523050A (ja) 2003-09-17 2007-08-16 カイアズマ・リミテッド 生物学的障壁を通した透過を容易にすることのできる組成物
WO2005034913A1 (fr) 2003-10-10 2005-04-21 Eisai Co., Ltd. Nouvelle composition de preparation liquide
WO2005041901A2 (fr) 2003-11-03 2005-05-12 Elixir Pharmaceuticals, Inc. Agents therapeutiques utilisant les agonistes de somatostatine
EP1682091B1 (fr) 2003-11-07 2017-03-29 Camurus Ab Compositions de lipides et de peptides cationiques
AR046773A1 (es) 2003-12-23 2005-12-21 Novartis Ag Formulaciones farmaceuticas de bisfosfonatos
KR20060130723A (ko) 2004-03-10 2006-12-19 쉐링 악티엔게젤샤프트 분자 분산된 드로스피레논을 포함하는 조성물
US20050209441A1 (en) 2004-03-22 2005-09-22 Lile Jackson D Process for promoting proper folding of human serum albumin using a human serum albumin ligand
US20070219131A1 (en) 2004-04-15 2007-09-20 Ben-Sasson Shmuel A Compositions capable of facilitating penetration across a biological barrier
MXPA06011871A (es) 2004-04-15 2007-10-08 Chiasma Inc Composiciones capaces de facilitar la penetracion a traves de una barrera biologica.
US20050256097A1 (en) 2004-05-11 2005-11-17 Kosan Biosciences, Inc. Pharmaceutical solution formulations containing 17-AAG
CN1960746A (zh) 2004-05-25 2007-05-09 阿尔扎公司 稳定性提高的含生物分子配方
US20050266087A1 (en) 2004-05-25 2005-12-01 Gunjan Junnarkar Formulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium
WO2005117928A1 (fr) 2004-05-30 2005-12-15 Cemines, Inc. Compositions et methodes de traitement du cancer de la peau
EP1765300A2 (fr) 2004-06-10 2007-03-28 Duramed Pharmaceuticals, Inc. Formulations de sumatriptan absorbables au travers des membranes biologiques, et methodes de production et d'utilisation desdites formulations
EP1778187B1 (fr) 2004-08-04 2012-05-23 Camurus Ab Compositions formant des dispersions non lamellaires
JP4993852B2 (ja) 2004-09-17 2012-08-08 サントリーホールディングス株式会社 ストレスに起因する行動異常を伴う症状あるいは疾患の予防又は改善作用を有する組成物
JP2008513513A (ja) 2004-09-21 2008-05-01 アネシヴァ， インコーポレイテッド ポリヌクレオチドの送達
BRPI0608173A2 (pt) 2005-02-24 2010-11-09 Elan Pharma Int Ltd composição, uso da mesma, e, método de produzir uma composição de docetaxel nanoparticulada ou análogo do mesmo
WO2006123360A2 (fr) 2005-03-01 2006-11-23 Sun Pharmaceutical Industries Limited Compositions pharmaceutiques a liberation prolongee
US7759312B2 (en) 2005-03-11 2010-07-20 Endo Pharmaceuticals Solutions Inc. Delivery of dry formulations of octreotide
EP1888043A4 (fr) 2005-03-11 2010-07-28 Endo Pharmaceuticals Solutions Preparation d'octreotide a liberation lente
US8232241B2 (en) 2005-05-23 2012-07-31 Mayo Foundation For Medical Education And Research Treating liver diseases
US7288520B2 (en) 2005-07-13 2007-10-30 Allergan, Inc. Cyclosporin compositions
US20070021325A1 (en) 2005-07-21 2007-01-25 Mediplex Corporation Drug formulation containing a solubilizer for enhancing solubility, absorption, and permeability
US20070066512A1 (en) 2005-09-12 2007-03-22 Dominique Verhelle Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
FR2891459B1 (fr) 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
JP2009514890A (ja) 2005-11-07 2009-04-09 マーティ・ファーマシューティカルズ・インク テトラヒドロカンナビノールの改良された送達
NO20220050A1 (no) 2005-11-21 2008-08-12 Novartis Ag Neuroendokrin tumorbehandling
KR20130024987A (ko) 2005-12-22 2013-03-08 노파르티스 아게 옥트레오티드 및 ２종 이상의 폴리락티드-코-글리콜리드 중합체를 포함하는 서방형 제제
AR059423A1 (es) 2006-02-09 2008-04-09 Univ Maryland Administracion oral de agentes terapeuticos usando agonistas de uniones impermeables
US20070190139A1 (en) 2006-02-13 2007-08-16 Intelgenx Corp. Delayed release pharmaceutical oral dosage form and method of making same
US20070224142A1 (en) 2006-03-22 2007-09-27 Swaile David F Hydrogenated castor oil based compositions as a replacement for petrolatum
CN101437518A (zh) 2006-04-06 2009-05-20 活跃生物药物学有限公司 药物组合物及其应用
ES2426445T3 (es) 2006-04-07 2013-10-23 Merrion Research Iii Limited Forma de dosificación oral sólida que contiene un potenciador
US8071136B2 (en) 2006-04-21 2011-12-06 Bioactives, Inc. Water-soluble pharmaceutical compositions of hops resins
CA2655273A1 (fr) 2006-06-08 2007-12-13 Novartis Ag Association d'analogues de la somatostatine avec un agoniste des recepteurs de la dopamine ou de l'hormone de croissance
CA2654566A1 (fr) 2006-06-09 2007-12-21 Merrion Research Iii Limited Forme posologique solide a administrer par voie orale contenant un activateur
US7998927B2 (en) 2006-06-23 2011-08-16 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
KR100816065B1 (ko) 2006-11-27 2008-03-24 동국제약 주식회사 초기 방출억제 특성이 우수한 서방출성 마이크로캡슐의제조방법 및 이에 의해 제조되는 마이크로캡슐
US9918934B2 (en) 2006-12-12 2018-03-20 Edgar Joel Acosta-Zara Linker-based lecithin microemulsion delivery vehicles
WO2008092084A2 (fr) 2007-01-26 2008-07-31 Centocor, Inc. Suspension non aqueuse injectable présentant une concentration élevée en agent thérapeutique
AU2008215659B2 (en) 2007-02-16 2012-11-01 Aska Pharmaceutical Co., Ltd. Pharmaceutical composition comprising microparticle oily suspension
BRPI0818004B8 (pt) 2007-10-16 2021-05-25 Biocon Ltd composição farmacêutica sólida administrável por via oral e o processo da mesma.
GB2454672A (en) 2007-11-13 2009-05-20 Mologic Ltd Chromogenic protease substrates
WO2009102443A2 (fr) 2008-02-15 2009-08-20 The Government Of The Usa, As Represented By The Secretary Of The Dept. Of Health & Human Services; Formulation d'acide octanoïque et procédés de traitement les employant
WO2009137080A1 (fr) 2008-05-07 2009-11-12 Merrion Research Iii Limited Compositions de composés apparentés à la gnrh et leurs procédés de préparation
CN102123697B (zh) 2008-08-18 2015-06-10 安特拉贝欧有限公司 用于口服给予蛋白质的方法和组合物
NZ591810A (en) 2008-09-17 2012-12-21 Chiasma Inc Pharmaceutical compositions and related methods of delivery the composition comprises a medium chain fatty acid
US20100151033A1 (en) * 2008-12-15 2010-06-17 Novartis Ag Octreotide depot formulation with constantly high exposure levels
RU2012108851A (ru) 2009-09-14 2013-10-27 Зинтес Гмбх Компрессионная пластинка с вариабельным углом
JP2011113487A (ja) 2009-11-30 2011-06-09 Hochiki Corp 警報器の設置方法、警報器および支持部材
WO2011112576A1 (fr) 2010-03-10 2011-09-15 Ambrilia Biopharma Inc. Microsphères pour une libération entretenue d'acétate d'octréotide
TWI633887B (zh) 2012-05-31 2018-09-01 大塚製藥股份有限公司 用於預防及／或治療多囊性腎臟病之藥物
CN104379150A (zh) 2012-06-21 2015-02-25 安吉奥金尼药品有限公司 缓解肿瘤症状的方法和组合物
WO2014049515A1 (fr) 2012-09-25 2014-04-03 Piramal Enterprises Limited Flavones à substitution pyrrolidine pour le traitement de maladies kystiques rénales
EP2914259A1 (fr) 2012-10-19 2015-09-09 Synta Pharmaceuticals Corp. Traitement de la polykystose rénale avec des composés inhibiteurs de la protéine hsp90
WO2016048984A1 (fr) 2014-09-25 2016-03-31 Cortendo Ab (Publ) Méthodes et compositions pour le traitement du syndrome de cushing basées sur le 2s,4r kétoconazole
HK1245115A1 (zh) 2014-12-10 2018-08-24 Amryt Endo, Inc. 口腔奥曲肽与其他治疗剂联合应用
PL3253401T3 (pl) * 2015-02-03 2025-08-04 Amryt Endo, Inc. Leczenie akromegalii oktreotydem doustnym
JP2017014206A (ja) 2015-06-30 2017-01-19 ナノアンティバイオティクス，インコーポレイテッド 腹水の治療
MA43800A (fr) 2016-01-21 2021-05-12 Chiasma Inc Octréotide par voie orale pour le traitement de maladies
IL265761B2 (en) 2016-10-21 2024-11-01 Amryt Endo Inc Oral terlipressin compositions for use in treatment of ascites
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods
US20220202911A1 (en) 2020-12-28 2022-06-30 Amryt Endo, Inc. Oral octreotide therapy in combination with digoxin or lisinopril
AU2023224281A1 (en) 2022-02-25 2024-10-10 Amryt Endo, Inc. Oral octreotide for treatment of disease

Also Published As

Publication number Publication date
DK3253401T3 (da) 2025-05-19
ZA201705877B (en) 2019-03-27
WO2016126830A1 (fr) 2016-08-11
US12251418B2 (en) 2025-03-18
US10238709B2 (en) 2019-03-26
US20210052691A1 (en) 2021-02-25
US11857595B2 (en) 2024-01-02
US20240245748A1 (en) 2024-07-25
IL277235A (en) 2020-10-29
EP3253401B1 (fr) 2025-04-02
US20220233630A1 (en) 2022-07-28
AU2016215350A1 (en) 2017-09-14
AU2024203939B2 (en) 2026-03-19
EP3253401A1 (fr) 2017-12-13
HRP20250645T1 (hr) 2025-07-18
US11338011B2 (en) 2022-05-24
HK1247818A1 (en) 2018-10-05
EP3253401A4 (fr) 2018-11-21
US20200390847A1 (en) 2020-12-17
AU2016215350B2 (en) 2021-11-25
FI3253401T3 (fi) 2025-07-09
AU2022201269B2 (en) 2024-03-14
PL3253401T3 (pl) 2025-08-04
ZA202301198B (en) 2024-05-30
NZ734894A (en) 2024-11-29
US20190298792A1 (en) 2019-10-03
LT3253401T (lt) 2025-07-10
SI3253401T1 (sl) 2025-07-31
MA41462B1 (fr) 2025-04-30
US11052126B2 (en) 2021-07-06
US20240245749A1 (en) 2024-07-25
SMT202500243T1 (it) 2025-07-22
AU2024203939A1 (en) 2024-07-04
US12246054B2 (en) 2025-03-11
AU2022201269A1 (en) 2022-03-17
US20240082343A1 (en) 2024-03-14
US20160220628A1 (en) 2016-08-04
ES3029566T3 (en) 2025-06-24
US10695397B2 (en) 2020-06-30
MD3253401T2 (ro) 2025-07-31
RS66942B1 (sr) 2025-07-31
US20220378867A1 (en) 2022-12-01
HUE071943T2 (hu) 2025-10-28
PT3253401T (pt) 2025-06-04
ZA201808086B (en) 2023-12-20
IL253706A0 (en) 2017-09-28
CA2975599A1 (fr) 2016-08-11
EP4527456A3 (fr) 2025-05-21
EP4527456A2 (fr) 2025-03-26
US11510963B1 (en) 2022-11-29

Similar Documents

Publication Publication Date Title
EP3380121A4 (fr) Méthode de traitement de troubles oculaires
EP3538130A4 (fr) Méthode de traitement de tumeur immunothérapeutique
FR25C1031I1 (fr) Traitement de maladies cholestatiques intrahepatiques
EP3658139A4 (fr) Méthodes de traitement de maladies hépatiques
EP3341080A4 (fr) Méthode de traitement du cancer
EP3273955A4 (fr) Traitement de maladies respiratoires
EP3390666A4 (fr) Compositions et méthodes de traitement de maladies rénales
MA41462A (fr) Méthode de traitement de maladies
IL257561A (en) Methods for treating inflammatory diseases
MA48996A (fr) Méthodes de traitement de maladies neurodégénératives
EP3375440A4 (fr) Méthode de traitement de la mucosite
IL253118A0 (en) Methods for treating inflammatory diseases
EP3820461A4 (fr) Méthode de traitement du cancer
MA42930A (fr) Traitement de maladies neurodégénératives
EP3373962A4 (fr) Compositions et méthodes de traitement de maladies auto-immunes et de cancers
EP3448365A4 (fr) Méthode de traitement de la constipation
EP3592224A4 (fr) Méthode permettant de surveiller le traitement de maladies neuropsychiatriques
IL257764B (en) Methods for treatment of diseases
EP3307280A4 (fr) Traitement de dysfonction sexuelle
MA41636A (fr) Méthode de traitement de la cholangite sclérosante primitive
EP2945616A4 (fr) Traitement de maladies pulmonaires
EP3703707A4 (fr) Méthode de traitement de troubles de type acide-base
EP3344258A4 (fr) Traitement de maladies auto-immunes et de maladies auto-inflammatoires
EP3316887A4 (fr) Inhibiteurs de gls1 pour le traitement de maladies
MA48862A (fr) Méthode de traitement de tumeur immunothérapeutique